Go Pro
→ Trump's gold order: the announcement they won't put on the front page (From Reagan Gold Group) (Ad)tc pixel Free PBYI Stock Alerts

Puma Biotechnology (PBYI) Financials

Puma Biotechnology logo
$7.90 -0.23 (-2.83%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$8.06 +0.16 (+2.03%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Puma Biotechnology

Annual Income Statements for Puma Biotechnology

This table shows Puma Biotechnology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -239 -276 -292 -114 -76 -60 -29 0.00 22 30 31
Consolidated Net Income / (Loss)		 -239 -276 -292 -114 -76 -60 -29 0.00 22 30 31
Net Income / (Loss) Continuing Operations		 -239 -276 -292 -114 -76 -60 -29 0.00 22 30 31
Total Pre-Tax Income 		-239 -276 -292 -114 -76 -60 -29 0.46 23 24 36
Total Operating Income		 -240 -277 -292 -95 -39 -30 1.29 24 33 31 37
Total Gross Profit		 0.00 0.00 22 216 235 186 189 173 173 166 170
Total Revenue		 0.00 0.00 28 251 272 225 253 228 236 230 228
Operating Revenue		 - - 28 251 272 225 253 228 236 230 228
Total Cost of Revenue		 0.00 0.00 5.57 35 37 39 64 55 63 64 58
Operating Cost of Revenue		 - - 5.57 35 37 39 64 55 63 64 58
Total Operating Expenses		 240 277 315 311 274 216 188 149 140 135 133
Selling, General & Admin Expense		 32 54 107 146 142 118 116 90 90 80 71
Research & Development Expense		 208 223 208 165 133 98 72 59 50 55 62
Total Other Income / (Expense), net		 1.00 0.59 0.44 -19 -36 -29 -30 -23 -9.97 -6.87 -1.52
Interest Expense		 - - 0.72 11 23 14 21 12 13 12 6.62
Interest & Investment Income		 0.97 0.96 1.26 1.80 2.85 0.49 0.16 0.81 2.61 4.72 4.08
Other Income / (Expense), net		 0.03 -0.37 -0.10 -9.71 -16 -16 -9.30 -12 0.76 0.86 1.03
Income Tax Expense		 - - - 0.02 0.05 0.21 0.32 0.46 1.08 -6.18 4.67
Basic Earnings per Share		 ($7.45) ($8.29) ($7.85) ($2.99) ($75,595.00) ($1.52) ($0.72) $0.00 $0.46 $0.62 $0.62
Weighted Average Basic Shares Outstanding		 32.13M 33.30M 37.17M 37.94M 38.77M 39.58M 40.64M 44.67M 47.13M 48.65M 50.01M
Diluted Earnings per Share		 ($7.45) ($8.29) ($7.85) ($2.99) - ($1.52) ($0.72) $0.00 $0.45 $0.62 $0.61
Weighted Average Diluted Shares Outstanding		 32.13M 33.30M 37.17M 37.94M 38.77M 39.58M 40.64M 44.93M 47.55M 49.10M 50.65M
Weighted Average Basic & Diluted Shares Outstanding		 32.13M 33.30M 37.17M 37.94M 38.77M 39.58M 40.64M 46.64M 48.21M 49.61M 50.88M

Quarterly Income Statements for Puma Biotechnology

This table shows Puma Biotechnology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 5.80 12 -4.82 -4.53 20 19 2.97 5.86 8.84 13 -3.75
Consolidated Net Income / (Loss)		 5.80 12 -4.82 -4.53 20 19 2.97 5.86 8.84 13 -3.75
Net Income / (Loss) Continuing Operations		 5.80 12 -4.82 -4.53 20 19 2.97 5.86 8.84 13 -3.75
Total Pre-Tax Income 		6.01 13 -4.60 -4.15 21 12 3.27 6.17 9.24 17 -3.43
Total Operating Income		 8.59 15 -2.30 -2.18 22 13 3.98 6.64 9.57 17 -3.83
Total Gross Profit		 43 48 33 36 51 45 35 40 42 52 34
Total Revenue		 56 72 44 47 81 59 46 52 54 75 45
Operating Revenue		 56 72 44 47 81 59 46 52 54 75 45
Total Cost of Revenue		 13 24 11 11 29 14 11 12 12 23 10
Operating Cost of Revenue		 13 24 11 11 29 14 11 12 12 23 10
Total Operating Expenses		 34 33 35 39 29 32 31 33 33 35 38
Selling, General & Admin Expense		 23 20 22 25 17 17 18 18 17 18 18
Research & Development Expense		 11 13 14 14 13 15 14 15 16 17 20
Total Other Income / (Expense), net		 -2.58 -1.99 -2.30 -1.97 -1.47 -1.13 -0.72 -0.47 -0.33 0.00 0.40
Interest Expense		 3.34 3.35 3.36 3.37 3.10 2.62 2.18 1.84 1.49 1.12 0.73
Interest & Investment Income		 0.69 0.72 0.97 1.24 1.28 1.23 1.10 0.96 1.04 0.98 1.00
Other Income / (Expense), net		 0.07 0.64 0.09 0.16 0.35 0.27 0.36 0.41 0.12 0.14 0.13
Income Tax Expense		 0.21 0.54 0.22 0.38 0.29 -7.07 0.29 0.31 0.40 3.67 0.33
Basic Earnings per Share		 $0.12 $0.26 ($0.10) ($0.09) $0.41 $0.40 $0.06 $0.12 $0.18 $0.26 ($0.07)
Weighted Average Basic Shares Outstanding		 47.52M 47.13M 48.19M 48.29M 49.01M 48.65M 49.60M 49.70M 50.34M 50.01M 50.85M
Diluted Earnings per Share		 $0.12 $0.25 ($0.10) ($0.09) $0.41 $0.40 $0.06 $0.12 $0.17 $0.26 ($0.07)
Weighted Average Diluted Shares Outstanding		 47.82M 47.55M 48.19M 48.29M 49.17M 49.10M 49.91M 50.14M 50.93M 50.65M 50.85M
Weighted Average Basic & Diluted Shares Outstanding		 47.57M 48.21M 48.24M 49.05M 49.09M 49.61M 49.64M 50.37M 50.39M 50.88M 50.90M

Annual Cash Flow Statements for Puma Biotechnology

This table details how cash moves in and out of Puma Biotechnology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -6.97 163 -113 27 -40 24 -22 3.50 7.88 -15 -40
Net Cash From Operating Activities		 -154 -142 -172 -24 22 0.77 21 -16 27 39 42
Net Cash From Continuing Operating Activities		 -154 -142 -172 -24 22 -1.23 21 -16 27 39 42
Net Income / (Loss) Continuing Operations		 -239 -276 -292 -114 -76 -60 -29 0.00 22 30 31
Consolidated Net Income / (Loss)		 -239 -276 -292 -114 -76 -60 -29 0.00 22 30 31
Depreciation Expense		 0.78 1.15 2.81 7.38 8.08 10 11 9.84 12 12 11
Non-Cash Adjustments To Reconcile Net Income		 95 118 109 87 67 36 40 19 12 7.73 6.59
Changes in Operating Assets and Liabilities, net		 -11 13 7.94 -5.14 23 13 -1.31 -44 -18 -11 -6.83
Net Cash From Investing Activities		 -86 142 -15 -58 5.16 33 -11 7.10 -19 -20 -36
Net Cash From Continuing Investing Activities		 -86 142 -15 -58 5.16 33 -11 7.10 -19 -20 -36
Purchase of Property, Plant & Equipment		 -1.18 -7.28 -0.43 -0.61 -0.31 -0.05 0.00 0.00 -0.14 -0.06 -0.07
Acquisitions		 - - -50 0.00 0.00 -10 0.00 -7.00 -13 0.00 0.00
Purchase of Investments		 -215 -82 -80 -108 -127 -30 -38 -4.84 -24 -76 -108
Sale and/or Maturity of Investments		 133 231 115 50 133 73 27 19 17 56 72
Net Cash From Financing Activities		 233 162 75 108 -67 -9.93 -32 12 0.00 -34 -45
Net Cash From Continuing Financing Activities		 233 162 75 108 -67 -9.93 -32 12 0.00 -34 -45
Repayment of Debt		 - - -1.58 -4.20 -93 -8.44 -110 0.00 0.00 -34 -45
Issuance of Common Equity		 233 162 27 7.65 1.35 0.07 0.00 13 0.00 0.15 0.13
Cash Interest Paid		 - - 0.34 8.06 12 9.70 10 10 12 11 5.82
Cash Income Taxes Paid		 - - - 0.02 0.05 0.21 0.32 0.38 0.74 1.22 1.52

Quarterly Cash Flow Statements for Puma Biotechnology

This table details how cash moves in and out of Puma Biotechnology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 22 2.29 -7.83 -9.60 0.11 1.96 -6.19 -8.37 -1.14 -24 6.56
Net Cash From Operating Activities		 11 10 11 1.03 11 16 3.61 14 9.69 14 15
Net Cash From Continuing Operating Activities		 11 10 11 1.03 11 16 3.61 14 9.69 14 15
Net Income / (Loss) Continuing Operations		 5.80 12 -4.82 -4.53 20 19 2.97 5.86 8.84 13 -3.75
Consolidated Net Income / (Loss)		 5.80 12 -4.82 -4.53 20 19 2.97 5.86 8.84 13 -3.75
Depreciation Expense		 2.88 2.89 2.90 2.91 2.88 2.84 2.80 2.76 2.72 2.66 2.58
Non-Cash Adjustments To Reconcile Net Income		 3.17 2.80 2.49 1.88 2.01 1.35 2.24 1.27 1.46 1.62 1.90
Changes in Operating Assets and Liabilities, net		 -1.23 -7.50 11 0.77 -14 -7.89 -4.40 4.20 -3.34 -3.29 15
Net Cash From Investing Activities		 11 -8.17 -19 0.70 0.26 -2.32 1.53 -11 0.51 -27 2.47
Net Cash From Continuing Investing Activities		 11 -8.17 -19 0.70 0.26 -2.32 1.53 -11 0.51 -27 2.47
Purchase of Property, Plant & Equipment		 -0.03 -0.05 0.00 -0.02 -0.02 -0.02 -0.06 -0.02 -0.03 0.04 0.00
Purchase of Investments		 -1.97 -11 -25 -20 -16 -15 -13 -22 -27 -47 -25
Sale and/or Maturity of Investments		 13 3.18 5.89 21 16 13 14 11 27 20 27
Net Cash From Financing Activities		 - - 0.00 -11 -11 -11 -11 -11 -11 -11 -11
Net Cash From Continuing Financing Activities		 - - 0.00 -11 -11 -11 -11 -11 -11 -11 -11
Repayment of Debt		 - - 0.00 -11 -11 -11 -11 -11 -11 -11 -11
Cash Interest Paid		 2.91 2.91 2.91 2.91 2.67 2.29 1.92 1.62 1.31 0.98 0.64
Cash Income Taxes Paid		 0.25 0.25 0.12 0.80 0.25 0.05 0.10 0.93 0.25 0.25 0.01

Annual Balance Sheets for Puma Biotechnology

This table presents Puma Biotechnology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 240 253 166 259 235 244 227 222 231 213 216
Total Current Assets		 224 236 106 203 166 146 140 134 156 148 163
Cash & Equivalents		 32 194 82 108 60 85 63 76 85 69 30
Restricted Cash		 - - - - 8.85 8.85 8.85 - - 0.00 2.09
Short-Term Investments		 184 35 - 57 52 8.10 19 4.87 11 32 68
Accounts Receivable		 - - 9.67 21 29 26 33 40 48 32 54
Inventories, net		 - - 2.03 2.63 3.17 3.45 7.11 4.53 7.08 8.72 5.52
Prepaid Expenses		 7.66 7.00 13 12 13 11 8.98 5.90 4.42 5.87 3.64
Other Current Assets		 - - - 1.79 0.48 3.64 0.45 2.43 0.91 0.09 0.26
Plant, Property, & Equipment, net		 2.38 5.15 4.47 3.96 3.30 2.48 1.76 1.15 0.86 0.52 0.19
Total Noncurrent Assets		 14 11 55 52 65 96 85 87 73 65 53
Noncurrent Note & Lease Receivables		 - - - - 19 16 14 11 7.79 4.58 5.37
Goodwill		 - - 48 44 40 74 66 71 61 51 41
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - - 0.00 7.08 3.83
Other Noncurrent Operating Assets		 9.60 6.85 1.99 7.75 2.00 1.75 1.35 2.07 2.73 0.28 2.83
Total Liabilities & Shareholders' Equity		 240 253 166 259 235 244 227 222 231 213 216
Total Liabilities		 34 43 112 225 217 250 229 200 177 121 86
Total Current Liabilities		 32 37 58 67 91 114 110 77 99 96 81
Short-Term Debt		 - - - - 0.00 14 - 0.00 34 45 23
Accounts Payable		 18 20 28 21 19 12 11 6.44 6.89 5.51 5.06
Accrued Expenses		 15 17 31 46 69 82 93 66 53 37 50
Other Current Liabilities		 - - - - 2.62 5.58 5.84 5.51 5.78 8.38 3.64
Total Noncurrent Liabilities		 1.39 5.51 54 158 127 136 119 123 78 25 4.71
Other Noncurrent Operating Liabilities		 - - - - 32 52 22 25 12 3.38 4.71
Commitments & Contingencies		 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 206 210 53 34 17 -5.95 -2.45 22 53 92 130
Total Preferred & Common Equity		 206 210 53 34 17 -5.95 -2.45 22 53 92 130
Total Common Equity		 206 210 53 34 17 -5.95 -2.45 22 53 92 130
Common Stock		 727 1,006 1,142 1,236 1,295 1,332 1,364 1,388 1,399 1,407 1,414
Retained Earnings		 -521 -797 -1,088 -1,202 -1,278 -1,338 -1,367 -1,367 -1,345 -1,315 -1,284
Accumulated Other Comprehensive Income / (Loss)		 -0.15 -0.01 - -0.01 0.06 0.00 -0.00 0.00 -0.00 0.01 0.04

Quarterly Balance Sheets for Puma Biotechnology

This table presents Puma Biotechnology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 204 214 205 221 196 195 203 193
Total Current Assets		 125 143 138 157 133 137 144 142
Cash & Equivalents		 82 77 67 67 63 55 54 36
Restricted Cash		 - - - - - 2.09 2.09 2.09
Short-Term Investments		 3.23 30 30 29 30 41 41 65
Accounts Receivable		 29 25 28 55 25 26 34 26
Inventories, net		 5.68 7.10 9.05 2.67 8.75 8.59 9.48 8.69
Prepaid Expenses		 3.68 3.92 3.49 2.54 5.32 3.89 3.83 3.41
Other Current Assets		 1.99 0.26 0.24 0.24 0.10 0.07 0.23 0.20
Plant, Property, & Equipment, net		 0.91 0.76 0.68 0.60 0.47 0.39 0.31 0.12
Total Noncurrent Assets		 77 70 67 63 63 58 59 50
Noncurrent Note & Lease Receivables		 8.54 7.02 6.23 5.42 3.72 2.83 6.15 4.57
Goodwill		 63 58 56 54 49 46 44 39
Noncurrent Deferred & Refundable Income Taxes		 - - - - 7.08 7.08 7.08 3.83
Other Noncurrent Operating Assets		 2.91 2.82 2.28 2.23 1.62 1.79 1.93 2.96
Total Liabilities & Shareholders' Equity		 204 214 205 221 196 195 203 193
Total Liabilities		 165 163 156 150 99 90 88 64
Total Current Liabilities		 67 98 104 110 87 79 83 60
Short-Term Debt		 23 45 45 45 45 34 34 11
Accounts Payable		 5.06 8.96 14 7.51 6.03 5.42 6.39 8.17
Accrued Expenses		 34 38 39 51 27 32 37 38
Other Current Liabilities		 5.86 6.18 6.46 6.90 8.44 7.88 5.51 1.91
Total Noncurrent Liabilities		 98 65 52 39 12 11 4.87 4.55
Other Noncurrent Operating Liabilities		 21 10 8.46 6.49 1.76 0.23 4.87 4.55
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 39 51 49 71 97 105 115 128
Total Preferred & Common Equity		 39 51 49 71 97 105 115 128
Total Common Equity		 39 51 49 71 97 105 115 128
Common Stock		 1,396 1,401 1,403 1,405 1,409 1,411 1,412 1,416
Retained Earnings		 -1,357 -1,350 -1,355 -1,334 -1,312 -1,306 -1,297 -1,288
Accumulated Other Comprehensive Income / (Loss)		 -0.00 -0.03 -0.03 0.03 -0.01 -0.01 0.02 -0.03

Annual Metrics And Ratios for Puma Biotechnology

This table displays calculated financial ratios and metrics derived from Puma Biotechnology's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 806.60% 8.47% -17.32% 12.46% -9.92% 3.34% -2.19% -0.91%
EBITDA Growth		 -69.15% -14.01% -6.18% 66.52% 51.34% 23.29% 109.11% 539.44% 113.12% -3.49% 13.64%
EBIT Growth		 -68.85% -15.28% -5.60% 64.32% 47.05% 16.35% 82.68% 240.29% 197.25% -4.70% 20.42%
NOPAT Growth		 -68.88% -15.11% -5.71% 67.63% 58.75% 22.14% 104.24% -88.50% 29,841.01% 25.17% -16.64%
Net Income Growth		 -68.55% -15.35% -5.78% 61.10% 33.44% 20.64% 51.45% 100.01% 1,079,450.00% 40.23% 2.75%
EPS Growth		 -57.51% -11.28% 5.31% 61.91% 0.00% 0.00% 52.63% 100.00% 0.00% 37.78% -1.61%
Operating Cash Flow Growth		 -100.08% 8.27% -21.72% 86.02% 192.83% -96.55% 2,571.41% -176.64% 270.65% 44.09% 7.41%
Free Cash Flow Firm Growth		 -138.46% -2.42% -32.94% 70.84% 108.18% -451.25% 38.16% -182.39% 134.29% 208.69% -6.74%
Invested Capital Growth		 44.32% -68.86% 165.77% 31.76% -159.66% -6.44% 102.87% 9,464.64% 51.91% 1.90% -5.12%
Revenue Q/Q Growth		 0.00% 0.00% 355.57% 24.55% -18.57% 23.99% 1.12% 4.74% 2.84% -5.38% 7.72%
EBITDA Q/Q Growth		 -6.33% -3.98% 3.36% 27.49% 48.57% -311.34% 121.96% -32.43% 69.56% -4.10% 7.49%
EBIT Q/Q Growth		 -6.40% -4.07% 3.08% 25.66% 44.75% -159.96% 69.53% -46.05% 116.76% -5.37% 10.42%
NOPAT Q/Q Growth		 -6.40% -4.08% 3.08% 32.24% 47.73% -1,321.98% 107.78% -99.47% 36.81% 27.44% -19.21%
Net Income Q/Q Growth		 -6.33% -4.13% 2.86% 22.72% 20.50% -6.75% 39.63% -99.98% 480.87% 30.28% -15.87%
EPS Q/Q Growth		 -4.63% -1.47% 3.92% 23.33% 0.00% 0.00% 40.00% -100.00% 462.50% 31.91% -18.67%
Operating Cash Flow Q/Q Growth		 -10.41% -5.93% 3.01% 63.89% -19.68% -90.31% 0.98% 45.32% 11.44% 15.26% -2.76%
Free Cash Flow Firm Q/Q Growth		 -9.24% -7.40% -21.11% 56.54% -60.74% -57.10% 42.42% -17.55% 3.09% 23.71% -7.06%
Invested Capital Q/Q Growth		 -95.90% -8.46% 150.07% -40.14% 61.80% 36.89% 103.61% -8.46% 9.22% 11.46% 1.41%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 79.87% 86.21% 86.48% 82.51% 74.84% 75.84% 73.40% 72.06% 74.53%
EBITDA Margin		 0.00% 0.00% -1,046.34% -38.64% -17.33% -16.08% 1.30% 9.24% 19.06% 18.81% 21.57%
Operating Margin		 0.00% 0.00% -1,056.13% -37.71% -14.34% -13.51% 0.51% 10.40% 13.85% 13.44% 16.33%
EBIT Margin		 0.00% 0.00% -1,056.50% -41.58% -20.30% -20.54% -3.16% 4.93% 14.17% 13.81% 16.78%
Profit (Net Income) Margin		 0.00% 0.00% -1,054.56% -45.25% -27.77% -26.65% -11.51% 0.00% 9.16% 13.14% 13.62%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.02% 100.07% 100.35% 101.12% 0.44% 95.22% 125.63% 86.95%
Interest Burden Percent		 99.60% 99.65% 99.82% 108.80% 136.69% 129.32% 359.62% 4.07% 67.89% 75.72% 93.36%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 99.56% 4.78% -25.63% 13.05%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -362.71% -652.38% 0.00% 0.00% 0.57% 68.07% 69.98% 59.31%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -177.42% -429.92% 0.00% 0.00% -0.60% -48.60% 120.16% 61.64%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 103.43% 360.33% 0.00% 0.00% -0.55% -10.53% -28.38% -31.34%
Return on Equity (ROE)		 -148.14% -132.75% -221.91% -259.28% -292.05% -1,042.30% 693.72% 0.02% 57.54% 41.60% 27.97%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -1,550.41% -390.12% 0.00% 0.00% -3,341.95% -195.29% 26.86% 68.09% 64.56%
Operating Return on Assets (OROA)		 0.00% 0.00% -139.84% -49.16% -22.37% -19.30% -3.40% 5.01% 14.76% 14.34% 17.84%
Return on Assets (ROA)		 0.00% 0.00% -139.59% -53.49% -30.60% -25.04% -12.37% 0.00% 9.54% 13.64% 14.48%
Return on Common Equity (ROCE)		 -148.14% -132.75% -221.91% -259.28% -292.05% -1,042.30% 693.72% 0.02% 57.54% 41.60% 27.97%
Return on Equity Simple (ROE_SIMPLE)		 -116.15% -131.54% -547.74% -331.06% -432.89% 1,008.15% 1,190.76% 0.01% 0.00% 32.87% 0.00%
Net Operating Profit after Tax (NOPAT)		 -168 -194 -205 -66 -27 -21 0.90 0.10 31 39 32
NOPAT Margin		 0.00% 0.00% -739.29% -26.40% -10.04% -9.45% 0.36% 0.05% 13.19% 16.88% 14.20%
Net Nonoperating Expense Percent (NNEP)		 -39.19% -36.30% -64.34% -185.29% -222.46% -208.73% -1,360.63% 1.17% 116.67% -50.18% -2.33%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 0.09% 20.30% 24.44% 21.22%
Cost of Revenue to Revenue		 0.00% 0.00% 20.13% 13.79% 13.52% 17.49% 25.16% 24.16% 26.60% 27.94% 25.47%
SG&A Expenses to Revenue		 0.00% 0.00% 385.38% 58.24% 52.02% 52.64% 45.94% 39.46% 38.17% 34.78% 31.02%
R&D to Revenue		 0.00% 0.00% 750.62% 65.68% 48.80% 43.38% 28.39% 25.98% 21.38% 23.84% 27.18%
Operating Expenses to Revenue		 0.00% 0.00% 1,136.01% 123.92% 100.82% 96.01% 74.33% 65.44% 59.55% 58.62% 58.20%
Earnings before Interest and Taxes (EBIT)		 -240 -277 -292 -104 -55 -46 -8.01 11 33 32 38
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -239 -273 -290 -97 -47 -36 3.30 21 45 43 49
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 12.34 5.39 69.60 22.62 19.52 0.00 0.00 8.93 3.85 1.63 2.30
Price to Tangible Book Value (P/TBV)		 12.34 5.39 749.91 0.00 0.00 0.00 0.00 0.00 0.00 3.65 3.37
Price to Revenue (P/Rev)		 0.00 0.00 134.00 3.09 1.25 1.81 0.49 0.85 0.87 0.65 1.31
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 96,528.89 9.54 4.94 9.64
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10.48% 20.22% 10.38%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 233.23 36.71 0.00 0.00 335.40 5.73 3.77 2.03 4.18
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 132.80 3.04 1.14 1.78 0.50 0.91 0.88 0.49 0.98
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 38.57 9.85 4.62 2.62 4.52
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 18.49 6.22 3.57 5.81
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 140.77 2,000.82 6.68 2.92 6.87
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 13.90 518.40 6.16 0.00 7.69 2.92 5.33
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 53.34 0.00 0.00 0.00 16.93 3.00 6.31
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.91 4.43 5.44 -16.52 -39.69 4.55 1.86 0.73 0.17
Long-Term Debt to Equity		 0.00 0.00 0.91 4.43 5.44 -14.12 -39.69 4.55 1.23 0.24 0.00
Financial Leverage		 -1.12 -1.09 -1.03 -0.58 -0.84 -3.22 0.53 0.91 0.22 -0.24 -0.51
Leverage Ratio		 1.25 1.18 1.59 4.85 9.54 41.62 -56.07 23.41 6.03 3.05 1.93
Compound Leverage Factor		 1.24 1.18 1.59 5.27 13.04 53.82 -201.63 0.95 4.09 2.31 1.80
Debt to Total Capital		 0.00% 0.00% 47.63% 81.57% 84.47% 106.44% 102.58% 81.98% 65.09% 42.12% 14.73%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 15.47% 0.00% 0.00% 22.21% 28.48% 14.73%
Long-Term Debt to Total Capital		 0.00% 0.00% 47.63% 81.57% 84.47% 90.98% 102.58% 81.98% 42.89% 13.64% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 52.37% 18.43% 15.53% -6.44% -2.58% 18.02% 34.91% 57.88% 85.27%
Debt to EBITDA		 0.00 0.00 -0.17 -1.57 -2.01 -2.72 29.46 4.66 2.22 1.55 0.46
Net Debt to EBITDA		 0.00 0.00 0.11 0.14 0.63 0.20 0.86 0.69 0.04 -0.83 -1.57
Long-Term Debt to EBITDA		 0.00 0.00 -0.17 -1.57 -2.01 -2.32 29.46 4.66 1.46 0.50 0.00
Debt to NOPAT		 0.00 0.00 -0.24 -2.29 -3.47 -4.62 107.52 947.01 3.21 1.72 0.69
Net Debt to NOPAT		 0.00 0.00 0.16 0.20 1.09 0.34 3.13 141.05 0.05 -0.93 -2.38
Long-Term Debt to NOPAT		 0.00 0.00 -0.24 -2.29 -3.47 -3.95 107.52 947.01 2.11 0.56 0.00
Altman Z-Score		 39.71 8.70 5.31 -4.15 -5.91 -6.24 -6.96 -6.54 -5.68 -6.03 -4.12
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.89 6.31 1.82 3.02 1.83 1.28 1.28 1.73 1.57 1.54 2.00
Quick Ratio		 6.65 6.13 1.57 2.77 1.55 1.04 1.05 1.57 1.45 1.38 1.86
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -179 -184 -244 -71 5.83 -20 -13 -36 12 38 35
Operating Cash Flow to CapEx		 -13,079.42% -1,945.22% -40,016.24% -3,958.13% 7,312.42% 1,680.43% 0.00% 0.00% 19,292.14% 69,496.43% 58,876.06%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -339.45 -6.49 0.25 -1.46 -0.60 -3.09 0.92 3.04 5.33
Operating Cash Flow to Interest Expense		 0.00 0.00 -239.54 -2.19 0.97 0.06 0.99 -1.37 2.03 3.13 6.31
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -240.14 -2.25 0.95 0.05 0.99 -1.37 2.02 3.12 6.30
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.13 1.18 1.10 0.94 1.08 1.02 1.04 1.04 1.06
Accounts Receivable Turnover		 0.00 0.00 0.00 16.49 10.96 8.27 8.72 6.26 5.34 5.77 5.33
Inventory Turnover		 0.00 0.00 0.00 14.88 12.71 11.89 12.06 9.47 10.80 8.15 8.17
Fixed Asset Turnover		 0.00 0.00 5.75 59.53 74.93 77.83 119.50 157.15 235.52 336.45 650.63
Accounts Payable Turnover		 0.00 0.00 0.23 1.43 1.85 2.52 5.48 6.26 9.41 10.39 11.01
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 22.14 33.29 44.13 41.86 58.32 68.30 63.23 68.46
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 24.53 28.73 30.70 30.26 38.54 33.79 44.78 44.68
Days Payable Outstanding (DPO)		 0.00 0.00 1,563.20 255.01 197.63 144.89 66.61 58.35 38.81 35.13 33.15
Cash Conversion Cycle (CCC)		 0.00 0.00 -1,563.20 -208.34 -135.61 -70.05 5.51 38.52 63.28 72.88 79.99
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -14 -24 16 21 -12 -13 0.38 36 55 56 53
Invested Capital Turnover		 0.00 0.00 -6.75 13.74 64.99 -17.60 -39.52 12.45 5.16 4.15 4.18
Increase / (Decrease) in Invested Capital		 11 -9.77 40 5.01 -33 -0.80 14 36 19 1.05 -2.87
Enterprise Value (EV)		 2,327 901 3,677 763 311 401 127 208 208 114 223
Market Capitalization		 2,543 1,130 3,710 776 341 408 124 193 206 150 300
Book Value per Share		 $6.35 $5.70 $1.42 $0.90 $0.45 ($0.15) ($0.06) $0.47 $1.12 $1.88 $2.59
Tangible Book Value per Share		 $6.35 $5.70 $0.13 ($0.26) ($0.59) ($2.01) ($1.68) ($1.07) ($0.16) $0.84 $1.77
Total Capital		 206 210 102 186 112 92 95 120 153 159 153
Total Debt		 0.00 0.00 48 152 95 98 97 98 100 67 23
Total Long-Term Debt		 0.00 0.00 48 152 95 84 97 98 66 22 0.00
Net Debt		 -216 -229 -33 -14 -30 -7.24 2.83 15 1.63 -36 -77
Capital Expenditures (CapEx)		 1.18 7.28 0.43 0.61 0.31 0.05 0.00 0.00 0.14 0.06 0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -25 -30 -34 -30 -45 -56 -61 -24 -5.14 -4.09 4.34
Debt-free Net Working Capital (DFNWC)		 191 199 48 136 75 46 30 57 91 97 104
Net Working Capital (NWC)		 191 199 48 136 75 32 30 57 57 52 81
Net Nonoperating Expense (NNE)		 71 82 87 47 48 39 30 0.10 9.49 8.63 1.32
Net Nonoperating Obligations (NNO)		 -220 -234 -38 -14 -30 -7.24 2.83 15 1.63 -36 -77
Total Depreciation and Amortization (D&A)		 0.96 4.15 2.81 7.38 8.08 10 11 9.84 12 12 11
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -121.52% -11.77% -16.54% -24.91% -23.91% -10.65% -2.18% -1.77% 1.90%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 173.57% 54.14% 27.72% 20.51% 12.02% 24.91% 38.53% 42.03% 45.52%
Net Working Capital to Revenue		 0.00% 0.00% 173.57% 54.14% 27.72% 14.16% 12.02% 24.91% 24.11% 22.37% 35.66%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($7.45) ($8.29) ($7.85) ($2.99) ($1.95) ($1.52) ($29,126.00) $0.00 $0.46 $0.62 $0.62
Adjusted Weighted Average Basic Shares Outstanding		 32.49M 36.95M 37.72M 38.50M 39.30M 40.26M 41.33M 44.67M 47.13M 48.65M 50.01M
Adjusted Diluted Earnings per Share		 ($7.45) ($8.29) ($7.85) ($2.99) ($1.95) ($1.52) $0.00 $0.00 $0.45 $0.62 $0.61
Adjusted Weighted Average Diluted Shares Outstanding		 32.49M 36.95M 37.72M 38.50M 39.30M 40.26M 41.33M 44.93M 47.55M 49.10M 50.65M
Adjusted Basic & Diluted Earnings per Share		 ($7.45) ($8.29) ($7.85) ($2.99) ($1.95) ($1.52) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 32.13M 33.30M 37.17M 37.94M 38.77M 39.58M 40.64M 46.64M 48.21M 49.61M 50.88M
Normalized Net Operating Profit after Tax (NOPAT)		 -168 -194 -205 -66 -27 -21 0.90 17 31 22 32
Normalized NOPAT Margin		 0.00% 0.00% -739.29% -26.40% -10.04% -9.45% 0.36% 7.28% 13.19% 9.41% 14.20%
Pre Tax Income Margin		 0.00% 0.00% -1,054.56% -45.24% -27.75% -26.56% -11.38% 0.20% 9.62% 10.46% 15.67%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -406.24 -9.50 -2.39 -3.29 -0.38 0.97 2.51 2.56 5.79
NOPAT to Interest Expense		 0.00 0.00 -284.27 -6.03 -1.18 -1.52 0.04 0.01 2.33 3.12 4.90
EBIT Less CapEx to Interest Expense		 0.00 0.00 -406.84 -9.56 -2.40 -3.29 -0.38 0.97 2.50 2.55 5.78
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -284.87 -6.09 -1.20 -1.52 0.04 0.01 2.32 3.12 4.89
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 13,850.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Puma Biotechnology

This table displays calculated financial ratios and metrics derived from Puma Biotechnology's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 47,509,765.00 47,571,332.00 48,207,162.00 48,238,850.00 49,046,723.00 - 49,610,799.00 49,638,093.00 50,370,723.00 - 50,876,487.00
DEI Adjusted Shares Outstanding		 47,509,765.00 47,571,332.00 48,207,162.00 48,238,850.00 49,046,723.00 - 49,610,799.00 49,638,093.00 50,370,723.00 - 50,876,487.00
DEI Earnings Per Adjusted Shares Outstanding		 0.12 0.26 -0.10 -0.09 0.41 - 0.06 0.12 0.18 - -0.07
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -1.73% 23.10% -17.07% -13.72% 43.53% -18.15% 5.12% 11.37% -32.36% 27.72% -2.59%
EBITDA Growth		 135.07% 456.78% -90.43% -88.73% 119.37% -10.12% 936.14% 1,008.36% -50.96% 20.83% -115.60%
EBIT Growth		 255.17% 303.41% -151.08% -140.64% 158.99% -11.70% 296.69% 448.29% -56.80% 26.52% -185.15%
NOPAT Growth		 394.34% 313.03% -140.74% -133.92% 162.87% 48.70% 325.36% 513.19% -57.92% -36.26% -173.89%
Net Income Growth		 1,710.00% 217.85% -443.68% -313.03% 250.53% 57.36% 161.77% 229.28% -56.47% -30.39% -226.19%
EPS Growth		 1,300.00% 208.70% -433.33% -280.00% 241.67% 60.00% 160.00% 233.33% -58.54% -35.00% -216.67%
Operating Cash Flow Growth		 -38.50% 36.08% 325.50% -68.84% 3.98% 49.28% -67.88% 1,271.18% -12.22% -7.61% 326.80%
Free Cash Flow Firm Growth		 94.75% 85.70% -179.39% 94.41% 959.41% 531.81% 71.28% -153.65% -67.94% -18.59% 253.26%
Invested Capital Growth		 27.33% 51.91% 0.00% -26.13% -0.14% 1.90% 38.51% 33.17% 4.29% -5.12% -37.64%
Revenue Q/Q Growth		 2.84% 28.62% -39.36% 7.58% 71.06% -26.65% -22.12% 13.97% 3.89% 38.51% -40.61%
EBITDA Q/Q Growth		 46.87% 58.89% -96.24% 28.45% 2,759.21% -34.90% -56.67% 37.40% 26.52% 60.40% -105.60%
EBIT Q/Q Growth		 73.95% 78.30% -114.30% 8.38% 1,208.55% -39.21% -68.14% 62.24% 37.50% 78.05% -121.44%
NOPAT Q/Q Growth		 84.16% 71.22% -111.35% 5.22% 1,527.08% -3.14% -82.80% 73.78% 45.34% 46.70% -119.94%
Net Income Q/Q Growth		 172.62% 111.66% -139.25% 5.94% 548.60% -4.98% -84.59% 96.87% 51.05% 51.94% -127.93%
EPS Q/Q Growth		 140.00% 108.33% -140.00% 10.00% 555.56% -2.44% -85.00% 100.00% 41.67% 52.94% -126.92%
Operating Cash Flow Q/Q Growth		 222.06% -1.51% 7.57% -90.87% 974.78% 41.39% -76.86% 289.87% -31.20% 48.82% 6.91%
Free Cash Flow Firm Q/Q Growth		 -140.67% -82.56% -834.53% 128.02% 79.79% -8.27% -162.15% 47.66% 207.44% 132.94% 17.00%
Invested Capital Q/Q Growth		 -3.64% 9.22% -24.19% -7.42% 30.26% 11.46% 3.05% -10.99% 2.01% 1.41% -32.27%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 76.33% 66.30% 75.49% 77.36% 63.87% 76.44% 77.06% 76.54% 77.65% 69.35% 76.74%
EBITDA Margin		 20.56% 25.39% 1.57% 1.88% 31.42% 27.89% 15.52% 18.71% 22.78% 26.38% -2.49%
Operating Margin		 15.30% 20.50% -5.25% -4.63% 27.41% 22.62% 8.66% 12.66% 17.57% 22.67% -8.54%
EBIT Margin		 15.43% 21.39% -5.05% -4.30% 27.84% 23.08% 9.44% 13.44% 17.78% 22.86% -8.25%
Profit (Net Income) Margin		 10.33% 17.00% -11.00% -9.62% 25.23% 32.68% 6.46% 11.17% 16.24% 17.81% -8.37%
Tax Burden Percent		 96.46% 95.81% 104.79% 109.11% 98.59% 157.75% 91.03% 94.97% 95.68% 78.55% 109.51%
Interest Burden Percent		 69.40% 82.93% 208.11% 205.19% 91.89% 89.77% 75.22% 87.50% 95.41% 99.18% 92.67%
Effective Tax Rate		 3.54% 4.19% 0.00% 0.00% 1.41% -57.75% 8.97% 5.03% 4.32% 21.45% 0.00%
Return on Invested Capital (ROIC)		 75.12% 101.38% -39.92% -15.61% 130.65% 147.95% 36.85% 63.50% 69.32% 74.38% -28.94%
ROIC Less NNEP Spread (ROIC-NNEP)		 58.06% 77.89% 29.51% -65.40% 162.65% 158.29% 39.54% 64.92% 70.07% 74.38% -27.31%
Return on Net Nonoperating Assets (RNNOA)		 27.76% 16.88% -5.35% -10.00% -13.42% -37.39% -12.95% -26.74% -31.40% -37.81% 15.94%
Return on Equity (ROE)		 102.89% 118.26% -45.27% -25.61% 117.23% 110.56% 23.89% 36.76% 37.92% 36.56% -13.00%
Cash Return on Invested Capital (CROIC)		 26.43% 26.86% -84.26% 66.06% 60.73% 68.09% 56.81% 88.71% 73.86% 64.56% 99.01%
Operating Return on Assets (OROA)		 17.57% 22.27% -5.34% -4.64% 31.97% 23.96% 10.71% 16.00% 17.80% 24.30% -9.64%
Return on Assets (ROA)		 11.76% 17.70% -11.64% -10.40% 28.96% 33.93% 7.33% 13.29% 16.25% 18.93% -9.78%
Return on Common Equity (ROCE)		 102.89% 118.26% -45.27% -25.61% 117.23% 110.56% 23.89% 36.76% 37.92% 36.56% -13.00%
Return on Equity Simple (ROE_SIMPLE)		 9.59% 0.00% 30.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 8.28 14 -1.61 -1.53 22 21 3.63 6.30 9.16 13 -2.68
NOPAT Margin		 14.76% 19.64% -3.68% -3.24% 27.03% 35.69% 7.88% 12.02% 16.81% 17.81% -5.98%
Net Nonoperating Expense Percent (NNEP)		 17.06% 23.49% -69.43% 49.79% -32.00% -10.34% -2.69% -1.42% -0.76% 0.00% -1.63%
Return On Investment Capital (ROIC_SIMPLE)		 - 9.26% -1.07% -1.11% 14.59% 13.25% 2.37% 4.21% 6.15% 8.79% -1.92%
Cost of Revenue to Revenue		 23.67% 33.70% 24.51% 22.64% 36.13% 23.56% 22.94% 23.46% 22.35% 30.65% 23.26%
SG&A Expenses to Revenue		 40.63% 27.96% 49.70% 53.04% 20.88% 28.14% 38.26% 34.42% 30.87% 24.36% 41.11%
R&D to Revenue		 20.40% 17.84% 31.04% 28.95% 15.58% 25.68% 30.13% 29.47% 29.21% 22.32% 44.17%
Operating Expenses to Revenue		 61.03% 45.80% 80.74% 81.99% 36.46% 53.81% 68.40% 63.89% 60.08% 46.68% 85.28%
Earnings before Interest and Taxes (EBIT)		 8.66 15 -2.21 -2.02 22 14 4.34 7.05 9.69 17 -3.70
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 12 18 0.69 0.89 25 16 7.14 9.81 12 20 -1.11
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.23 3.85 5.01 3.24 1.76 1.63 1.51 1.63 2.32 2.30 2.53
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 7.14 3.65 3.03 2.91 3.74 3.37 3.63
Price to Revenue (P/Rev)		 0.55 0.87 1.13 0.72 0.51 0.65 0.63 0.72 1.26 1.31 1.43
Price to Earnings (P/E)		 33.62 9.54 16.62 18.03 5.38 4.94 3.86 3.51 7.23 9.64 13.33
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 2.97% 10.48% 6.02% 5.55% 18.58% 20.22% 25.92% 28.46% 13.83% 10.38% 7.50%
Enterprise Value to Invested Capital (EV/IC)		 2.71 3.77 5.90 3.81 2.07 2.03 1.86 2.27 3.90 4.18 6.45
Enterprise Value to Revenue (EV/Rev)		 0.60 0.88 1.09 0.67 0.43 0.49 0.46 0.49 0.97 0.98 1.02
Enterprise Value to EBITDA (EV/EBITDA)		 5.16 4.62 6.41 4.69 2.31 2.62 2.16 1.99 4.47 4.52 5.68
Enterprise Value to EBIT (EV/EBIT)		 8.87 6.22 9.17 7.42 3.10 3.57 2.80 2.47 5.90 5.81 7.69
Enterprise Value to NOPAT (EV/NOPAT)		 6.01 6.68 10.19 9.00 3.42 2.92 2.42 2.22 5.10 6.87 9.42
Enterprise Value to Operating Cash Flow (EV/OCF)		 5.64 7.69 6.92 4.42 3.09 2.92 3.44 2.64 4.76 5.33 4.34
Enterprise Value to Free Cash Flow (EV/FCFF)		 11.49 16.93 0.00 4.91 3.41 3.00 3.80 2.93 5.39 6.31 5.01
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 2.56 1.86 1.96 1.84 1.10 0.73 0.58 0.43 0.29 0.17 0.09
Long-Term Debt to Equity		 1.98 1.23 1.07 0.90 0.46 0.24 0.11 0.10 0.00 0.00 0.00
Financial Leverage		 0.48 0.22 -0.18 0.15 -0.08 -0.24 -0.33 -0.41 -0.45 -0.51 -0.58
Leverage Ratio		 6.61 6.03 4.20 5.14 3.86 3.05 2.77 2.61 2.27 1.93 1.72
Compound Leverage Factor		 4.59 5.00 8.74 10.54 3.55 2.74 2.08 2.28 2.17 1.92 1.60
Debt to Total Capital		 71.93% 65.09% 66.24% 64.74% 52.34% 42.12% 36.57% 29.99% 22.63% 14.73% 8.08%
Short-Term Debt to Total Capital		 16.42% 22.21% 30.02% 32.95% 30.39% 28.48% 29.61% 22.73% 22.63% 14.73% 8.08%
Long-Term Debt to Total Capital		 55.52% 42.89% 36.22% 31.79% 21.95% 13.64% 6.96% 7.27% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 28.07% 34.91% 33.76% 35.26% 47.66% 57.88% 63.43% 70.01% 77.37% 85.27% 91.92%
Debt to EBITDA		 3.75 2.22 2.60 2.83 1.73 1.55 1.12 0.76 0.74 0.46 0.28
Net Debt to EBITDA		 0.44 0.04 -0.24 -0.31 -0.46 -0.83 -0.79 -0.91 -1.37 -1.57 -2.25
Long-Term Debt to EBITDA		 2.89 1.46 1.42 1.39 0.72 0.50 0.21 0.19 0.00 0.00 0.00
Debt to NOPAT		 4.37 3.21 4.14 5.44 2.56 1.72 1.26 0.85 0.84 0.69 0.46
Net Debt to NOPAT		 0.51 0.05 -0.38 -0.60 -0.68 -0.93 -0.89 -1.01 -1.56 -2.38 -3.74
Long-Term Debt to NOPAT		 3.37 2.11 2.26 2.67 1.07 0.56 0.24 0.21 0.00 0.00 0.00
Altman Z-Score		 -7.27 -5.93 -6.61 -7.42 -6.27 -6.31 -6.93 -6.55 -5.56 -4.45 -4.69
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.86 1.57 1.46 1.32 1.42 1.54 1.53 1.73 1.74 2.00 2.38
Quick Ratio		 1.69 1.45 1.34 1.20 1.37 1.38 1.37 1.54 1.55 1.86 2.14
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2.54 -4.64 -43 12 22 20 -12 -6.52 7.00 16 19
Operating Cash Flow to CapEx		 39,314.81% 23,233.33% 0.00% 5,135.00% 55,190.00% 97,543.75% 5,921.31% 70,410.00% 37,265.38% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -0.76 -1.38 -12.91 3.60 7.05 7.64 -5.72 -3.55 4.70 14.58 26.11
Operating Cash Flow to Interest Expense		 3.18 3.12 3.35 0.30 3.56 5.95 1.66 7.67 6.51 12.89 21.09
Operating Cash Flow Less CapEx to Interest Expense		 3.17 3.10 3.35 0.30 3.55 5.95 1.63 7.65 6.49 12.92 21.09
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.14 1.04 1.06 1.08 1.15 1.04 1.13 1.19 1.00 1.06 1.17
Accounts Receivable Turnover		 8.04 5.34 9.22 7.38 5.83 5.77 9.35 8.81 4.81 5.33 8.82
Inventory Turnover		 9.92 10.80 8.48 7.07 17.91 8.15 8.10 7.47 8.06 8.17 6.65
Fixed Asset Turnover		 209.35 235.52 299.38 264.51 323.04 336.45 378.08 445.81 467.98 650.63 759.79
Accounts Payable Turnover		 5.52 9.41 6.71 5.54 11.90 10.39 8.57 6.96 7.05 11.01 8.18
Days Sales Outstanding (DSO)		 45.40 68.30 39.59 49.46 62.65 63.23 39.02 41.41 75.94 68.46 41.37
Days Inventory Outstanding (DIO)		 36.80 33.79 43.05 51.60 20.38 44.78 45.04 48.87 45.29 44.68 54.86
Days Payable Outstanding (DPO)		 66.09 38.81 54.36 65.88 30.67 35.13 42.59 52.43 51.80 33.15 44.64
Cash Conversion Cycle (CCC)		 16.12 63.28 28.29 35.19 52.36 72.88 41.47 37.85 69.43 79.99 51.60
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 50 55 42 39 50 56 58 51 53 53 36
Invested Capital Turnover		 5.09 5.16 10.86 4.82 4.83 4.15 4.67 5.28 4.12 4.18 4.84
Increase / (Decrease) in Invested Capital		 11 19 42 -14 -0.07 1.05 16 13 2.16 -2.87 -22
Enterprise Value (EV)		 137 208 246 147 104 114 108 117 205 223 233
Market Capitalization		 125 206 255 157 125 150 147 170 267 300 325
Book Value per Share		 $0.82 $1.12 $1.06 $1.01 $1.45 $1.88 $1.96 $2.11 $2.29 $2.59 $2.52
Tangible Book Value per Share		 ($0.52) ($0.16) ($0.15) ($0.16) $0.36 $0.84 $0.98 $1.18 $1.42 $1.77 $1.76
Total Capital		 138 153 151 138 149 159 153 150 149 153 140
Total Debt		 99 100 100 89 78 67 56 45 34 23 11
Total Long-Term Debt		 77 66 55 44 33 22 11 11 0.00 0.00 0.00
Net Debt		 12 1.63 -9.23 -9.86 -21 -36 -39 -53 -63 -77 -92
Capital Expenditures (CapEx)		 0.03 0.05 0.00 0.02 0.02 0.02 0.06 0.02 0.03 -0.04 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.37 -5.14 -17 -18 -4.98 -4.09 -1.99 -6.64 -1.91 4.34 -9.83
Debt-free Net Working Capital (DFNWC)		 81 91 90 79 92 97 91 91 95 104 94
Net Working Capital (NWC)		 58 57 45 33 46 52 46 57 61 81 83
Net Nonoperating Expense (NNE)		 2.48 1.91 3.21 3.00 1.45 1.78 0.65 0.45 0.32 -0.00 1.07
Net Nonoperating Obligations (NNO)		 12 1.63 -9.23 -9.86 -21 -36 -39 -53 -63 -77 -92
Total Depreciation and Amortization (D&A)		 2.88 2.89 2.90 2.91 2.88 2.84 2.80 2.76 2.72 2.66 2.58
Debt-free, Cash-free Net Working Capital to Revenue		 -1.91% -2.18% -7.50% -8.25% -2.04% -1.77% -0.86% -2.79% -0.90% 1.90% -4.33%
Debt-free Net Working Capital to Revenue		 35.20% 38.53% 39.79% 35.94% 37.67% 42.03% 39.18% 38.43% 44.61% 45.52% 41.29%
Net Working Capital to Revenue		 25.31% 24.11% 19.78% 15.25% 19.06% 22.37% 19.70% 24.14% 28.70% 35.66% 36.32%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.12 $0.26 ($0.10) ($0.09) $0.41 $0.40 $0.06 $0.12 $0.18 $0.26 ($0.07)
Adjusted Weighted Average Basic Shares Outstanding		 47.52M 47.13M 48.19M 48.29M 49.01M 48.65M 49.60M 49.70M 50.34M 50.01M 50.85M
Adjusted Diluted Earnings per Share		 $0.12 $0.25 ($0.10) ($0.09) $0.41 $0.40 $0.06 $0.12 $0.17 $0.26 ($0.07)
Adjusted Weighted Average Diluted Shares Outstanding		 47.82M 47.55M 48.19M 48.29M 49.17M 49.10M 49.91M 50.14M 50.93M 50.65M 50.85M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 47.57M 48.21M 48.24M 49.05M 49.09M 49.61M 49.64M 50.37M 50.39M 50.88M 50.90M
Normalized Net Operating Profit after Tax (NOPAT)		 8.28 14 -1.61 -1.53 22 9.36 3.63 6.30 9.16 13 -2.68
Normalized NOPAT Margin		 14.76% 19.64% -3.68% -3.24% 27.03% 15.84% 7.88% 12.02% 16.81% 17.81% -5.98%
Pre Tax Income Margin		 10.71% 17.74% -10.50% -8.82% 25.59% 20.72% 7.10% 11.76% 16.97% 22.67% -7.65%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 2.59 4.60 -0.66 -0.60 7.23 5.20 1.99 3.84 6.51 15.41 -5.06
NOPAT to Interest Expense		 2.48 4.23 -0.48 -0.45 7.02 8.04 1.67 3.43 6.15 12.01 -3.67
EBIT Less CapEx to Interest Expense		 2.59 4.59 -0.66 -0.61 7.23 5.20 1.97 3.82 6.49 15.45 -5.06
NOPAT Less CapEx to Interest Expense		 2.47 4.21 -0.48 -0.46 7.02 8.04 1.64 3.42 6.13 12.04 -3.67
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Puma Biotechnology (NASDAQ:PBYI) showed a sharp improvement in profitability over the last year, but the latest quarter also showed some sequential pressure in revenue and a meaningful drop in cash versus year-end. For retail investors, the big picture is mixed: the business is still generating solid operating cash flow, but earnings and the balance sheet have become more fragile compared with the strong fourth quarter of 2025.

  • Q1 2026 was profitable on an operating-cash basis: Puma produced $15.4 million in operating cash flow and $2.5 million in investing cash flow, helping lift cash during the quarter even though financing activity remained negative.
  • Gross margin remains strong: Q1 2026 revenue was $44.8 million against cost of revenue of $10.4 million, leaving $34.4 million in gross profit, or roughly a 77% gross margin.
  • Debt has come down a lot from a year ago: Total liabilities fell to $64.3 million in Q1 2026 from $149.6 million in Q3 2024. Short-term debt also dropped sharply from $45.3 million in Q1 2025 to $11.3 million in Q1 2026.
  • Cash and investments remain substantial: As of Q1 2026, Puma had $36.2 million in cash, $2.1 million in restricted cash, and $65.4 million in short-term investments, giving it meaningful liquidity despite recent earnings volatility.
  • Operating income swung from a loss to a profit in late 2025: After operating losses in early 2025, the company posted $17.1 million in operating income in Q4 2025, showing that the core business can still generate strong leverage when revenue is healthy.
  • Revenue was improving through 2025 before the latest dip: Revenue rose from $46.0 million in Q1 2025 to $75.5 million in Q4 2025 before pulling back to $44.8 million in Q1 2026.
  • Quarterly results have been volatile: Revenue moved from $43.8 million in Q1 2024 to $80.5 million in Q3 2024, then ranged from the mid-$40 millions to mid-$70 millions through 2025 and early 2026. That kind of volatility can make forecasting difficult.
  • Accounts receivable remain large: Q1 2026 accounts receivable were $26.3 million, which is sizable relative to quarterly revenue and worth watching for collection efficiency.
  • Goodwill is a meaningful asset on the balance sheet: Goodwill stood at $39.0 million in Q1 2026. That does not hurt cash flow directly, but it can become a concern if future performance weakens and impairments are needed.
  • Share count has been fairly stable: Weighted average diluted shares were 50.8 million in Q1 2026 versus 49.1 million in Q4 2024, so dilution has been limited recently.
  • Q1 2026 turned back to a net loss: Puma reported a net loss of $3.8 million, or $(0.07) per share, after earning $13.4 million in Q4 2025.
  • Operating income fell sharply quarter over quarter: Operating income dropped from $17.1 million in Q4 2025 to a loss of $3.8 million in Q1 2026, indicating weaker operating momentum.
  • Cash declined versus year-end: Cash and equivalents fell to $36.2 million from $53.5 million in Q3 2025 and $63.0 million in Q1 2025, showing that the balance sheet buffer has been shrinking.
  • Retained earnings remain deeply negative: Retained earnings were $(1.29) billion in Q1 2026, reflecting a long history of cumulative losses and underscoring that profitability has not yet been consistently durable.
  • Interest expense still matters: Q1 2026 interest expense was $731,000, and the company still carried $11.3 million of short-term debt, so leverage is lower than before but not eliminated.
  • Quarterly operating cash flow is not fully stable: Operating cash flow was strong in Q1 2026 and 2025, but the swing in reported earnings and working capital means investors should not assume consistency yet.

Bottom line: Puma Biotechnology has made real progress on debt reduction and can still generate positive operating cash flow, but the latest quarter showed a return to losses and lower cash than a year ago. Investors should watch whether Q2 2026 can restore the Q4 2025 earnings momentum and whether revenue stabilizes at a level that supports sustained profitability.

07/10/26 06:05 AM ETAI Generated. May Contain Errors.

Puma Biotechnology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Puma Biotechnology's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Puma Biotechnology's net income appears to be on a downward trend, with a most recent value of $31.11 million in 2025, falling from -$239.28 million in 2015. The previous period was $30.28 million in 2024. View Puma Biotechnology's forecast to see where analysts expect Puma Biotechnology to go next.

Puma Biotechnology's total operating income in 2025 was $37.30 million, based on the following breakdown:
  • Total Gross Profit: $170.21 million
  • Total Operating Expenses: $132.92 million

Over the last 10 years, Puma Biotechnology's total revenue changed from $0.00 in 2015 to $228.37 million in 2025, a change of 22,837,100,000.0%.

Puma Biotechnology's total liabilities were at $85.96 million at the end of 2025, a 29.1% decrease from 2024, and a 154.1% increase since 2015.

In the past 10 years, Puma Biotechnology's cash and equivalents has ranged from $29.64 million in 2025 to $194.49 million in 2016, and is currently $29.64 million as of their latest financial filing in 2025.

Over the last 10 years, Puma Biotechnology's book value per share changed from 6.35 in 2015 to 2.59 in 2025, a change of -59.3%.


Related Companies

Financial statements for NASDAQ:PBYI last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Is the fix for AI's runaway power problem your golden ticket?
The government just committed $200 billion to building computer chips on American soil - one of the largest te...
Eagle Publishing | Sponsoredtc pixel
Move your money (NOT into the next AI IPO)
While headlines focus on AI IPOs, the world's largest investors are moving capital into one asset at the faste...
Stansberry Research | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Executive order could send gold to 6,000 per ounce
Executive Order 14330 will allow Americans to hold precious metals inside 401(k)s for the first time ever - an...
Cedar Gold Group | Sponsoredtc pixel
The President banned this company
The President banned one company's technology. The Secretary of Defense called it a national security threat. ...
Behind the Markets | Sponsoredtc pixel